Association of decreased serum brain-derived neurotrophic factor (BDNF) concentrations in early pregnancy with antepartum depression

BMC Psychiatry

Michelle A Williams³  Chunfang Qiu¹  Karin Hevner¹  Yasmin V Barrios³  Sixto E Sanchez⁴  Marta B Rondon²  Qiu-Yue Zhong³  Bizu Gelaye³  Jenny Fung³ 

[1] Center for Perinatal Studies, Swedish Medical Center, Seattle, WA, USA;Department of Medicine, Cayetano Heredia Peruvian University, Lima, Peru;Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA;Asociación Civil PROESA, Lima, Peru

关键词: Maternal depression;    BDNF;    Biomarker;    Peru;   

Others  :  1137832
DOI  :  10.1186/s12888-015-0428-7

 received in 2014-11-30, accepted in 2015-02-20,  发布年份 2015

【 摘 要 】

Background

Antepartum depression is one of the leading causes of maternal morbidity and mortality in the prenatal period. There is accumulating evidence for the role of brain-derived neurotrophic factor (BDNF) in the pathophysiology of depression. The present study examines the extent to which maternal early pregnancy serum BDNF levels are associated with antepartum depression.

Method

A total of 968 women were recruited and interviewed in early pregnancy. Antepartum depression prevalence and symptom severity were assessed using the Patient Health Questionnaire-9 (PHQ-9) scale. Maternal serum BDNF levels were measured using a competitive enzyme-linked immunosorbent assay (ELISA). Logistic regression procedures were performed to estimate odds ratios (OR) and 95% confidence intervals (95% CI) adjusted for confounders.

Results

Maternal early pregnancy serum BDNF levels were significantly lower in women with antepartum depression compared to women without depression (mean ± standard deviation [SD]: 20.78 ± 5.97 vs. 21.85 ± 6.42 ng/ml, p = 0.024). Lower BDNF levels were associated with increased odds of maternal antepartum depression. After adjusting for confounding, women whose serum BDNF levels were in the lowest three quartiles (<17.32 ng/ml) had 1.61-fold increased odds (OR = 1.61, 95% CI: 1.13, 2.30) of antepartum depression as compared with women whose BDNF levels were in the highest quartile (>25.31 ng/ml). There was no evidence of an association of BDNF levels with depression symptom severity.

Conclusions

Lower maternal serum BDNF levels in early pregnancy are associated with antepartum depression. These findings may point toward new therapeutic opportunities and BDNF should be assessed as a potential biomarker for risk prediction and monitoring response to treatment for antepartum depression.

【 授权许可】

   
2015 Fung et al.; licensee BioMed Central.

【 参考文献 】

• [1]Bowen A, Muhajarine N: Antenatal depression. Can Nurse 2006, 102(9):26-30.
• [2]Evans J, Heron J, Francomb H, Oke S, Golding J: Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001, 323(7307):257-60.
• [3]Fisher J, Cabral De Mello M, Patel V, Rahman A, Tran T, Holton S, et al.: Prevalence and determinants of common perinatal mental disorders in women in low- and lower-middle-income countries: a systematic review. Bull World Health Organ 2012, 90(2):139G-49.
• [4]Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ: A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry 2010, 67(10):1012-24.
• [5]Rahman A, Iqbal Z, Harrington R: Life events, social support and depression in childbirth: perspectives from a rural community in the developing world. Psychol Med 2003, 33(7):1161-7.
• [6]Fisher J, Mello MCD, Patel V, Rahman A, Tran T, Holton S, et al.: Prevalence and determinants of common perinatal mental disorders in women in low-and lower-middle-income countries: a systematic review. Bull World Health Organ 2012, 90(2):139-49.
• [7]Bindt C, Appiah-Poku J, Te Bonle M, Schoppen S, Feldt T, Barkmann C, et al.: Antepartum depression and anxiety associated with disability in African women: cross-sectional results from the CDS study in Ghana and Côte d’Ivoire. PLoS One 2012, 7(10):e48396.
• [8]Horrigan TJ, Schroeder AV, Schaffer RM: The triad of substance abuse, violence, and depression are interrelated in pregnancy. J Subst Abuse Treat 2000, 18(1):55-8.
• [9]Llewellyn AM, Stowe ZN, Nemeroff CB: Depression during pregnancy and the puerperium. J Clin Psychiatry 1997, 58(Suppl 15):26-32.
• [10]Barrio L, Burt V: Depression in pregnancy: Strategies for primary care management. Dealing with an underdiagnosed undertreated problem. Women’s Health Prim Care 2000, 3:490-8.
• [11]Hoffman S, Hatch MC: Depressive symptomatology during pregnancy: evidence for an association with decreased fetal growth in pregnancies of lower social class women. Health Psychol 2000, 19(6):535-43.
• [12]Kurki T, Hiilesmaa V, Raitasalo R, Mattila H, Ylikorkala O: Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol 2000, 95(4):487-90.
• [13]Najman JM, Andersen MJ, Bor W, O’Callaghan MJ, Williams GM: Postnatal depression-myth and reality: maternal depression before and after the birth of a child. Soc Psychiatry Psychiatr Epidemiol 2000, 35(1):19-27.
• [14]Cripe SM, Frederick IO, Qiu C, Williams MA: Risk of preterm delivery and hypertensive disorders of pregnancy in relation to maternal co-morbid mood and migraine disorders during pregnancy. Paediatr Perinat Epidemiol 2011, 25(2):116-23.
• [15]Qiu C, Sanchez SE, Lam N, Garcia P, Williams MA: Associations of depression and depressive symptoms with preeclampsia: results from a Peruvian case–control study. BMC Womens Health 2007, 7:15. BioMed Central Full Text
• [16]Sanchez SE, Puente GC, Atencio G, Qiu C, Yanez D, Gelaye B, et al.: Risk of spontaneous preterm birth in relation to maternal depressive, anxiety, and stress symptoms. J Reprod Med 2013, 58(1–2):25-33.
• [17]Chung TK, Lau TK, Yip AS, Chiu HF, Lee DT: Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med 2001, 63(5):830-4.
• [18]Davalos DB, Yadon CA, Tregellas HC: Untreated prenatal maternal depression and the potential risks to offspring: a review. Arch Womens Ment Health 2012, 15(1):1-14.
• [19]Lusskin SI, Pundiak TM, Habib SM: Perinatal depression: hiding in plain sight. Can J Psychiatry 2007, 52(8):479-88.
• [20]Preti A, Cardascia L, Zen T, Pellizzari P, Marchetti M, Favaretto G, et al.: Obstetric complications in patients with depression–a population-based case–control study. J Affect Disord 2000, 61(1–2):101-6.
• [21]Steer RA, Scholl TO, Hediger ML, Fischer RL: Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol 1992, 45(10):1093-9.
• [22]Larsson C, Sydsjo G, Josefsson A: Health, sociodemographic data, and pregnancy outcome in women with antepartum depressive symptoms. Obstet Gynecol 2004, 104(3):459-66.
• [23]Barros MC, Mitsuhiro SS, Chalem E, Laranjeira RR, Guinsburg R: Depression during gestation in adolescent mothers interferes with neonatal neurobehavior. Rev Bras Psiquiatr 2013, 35(4):353-9.
• [24]Binder DK, Scharfman HE: Brain-derived neurotrophic factor. Growth Factors 2004, 22(3):123-31.
• [25]Castren E, Rantamaki T: The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol 2010, 70(5):289-97.
• [26]Duman RS, Heninger GR, Nestler EJ: A molecular and cellular theory of depression. Arch Gen Psychiatry 1997, 54(7):597-606.
• [27]Sen S, Duman R, Sanacora G: Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008, 64(6):527-32.
• [28]Bocchio-Chiavetto L, Bagnardi V, Zanardini R, Molteni R, Nielsen MG, Placentino A, et al.: Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatr 2010, 11(6):763-73.
• [29]Figueira P, Fernandes Malloy-Diniz L, Aurélio Romano-Silva M, Silva Neves F, Corrêa H: Postpartum depression and comorbid disorders: Frequency and relevance to clinical management. Arch Womens Ment Health 2009, 12(6):451.
• [30]Gazal M, Motta LS, Wiener CD, Fernandes JC, Quevedo LÁ, Jansen K, et al.: Brain-derived neurotrophic factor in post-partum depressive mothers. Neurochem Res 2012, 37(3):583-7.
• [31]Pinheiro RT, Pinheiro KAT, da Cunha Coelho FM, de Ávila QL, Gazal M, da Silva RA, et al.: Brain-Derived Neurotrophic Factor levels in women with postpartum affective disorder and suicidality. Neurochem Res 2012, 37(10):2229-34.
• [32]Kroenke K, Spitzer RL, Williams JB: The Phq‐9. J Gen Intern Med 2001, 16(9):606-13.
• [33]Spitzer RL, Kroenke K, Williams JB, Group PHQPCS: Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. JAMA 1999, 282(18):1737-44.
• [34]Furukawa TA: Assessment of mood: guides for clinicians. J Psychosom Res 2010, 68(6):581-9.
• [35]Flynn HA, Sexton M, Ratliff S, Porter K, Zivin K: Comparative performance of the Edinburgh Postnatal Depression Scale and the Patient Health Questionnaire-9 in pregnant and postpartum women seeking psychiatric services. Psychiatry Res 2011, 187(1):130-4.
• [36]Chen T, Huang F, Chang C, Chung H: Using the PHQ-9 for depression screening and treatment monitoring for Chinese Americans in primary care. Psychiatr Serv 2006, 57(7):976-81.
• [37]Huang FY, Chung H, Kroenke K, Delucchi KL, Spitzer RL: Using the patient health questionnaire‐9 to measure depression among racially and ethnically diverse primary care patients. J Gen Intern Med 2006, 21(6):547-52.
• [38]Wulsin L, Somoza E, Heck J: The feasibility of using the Spanish PHQ-9 to screen for depression in primary care in Honduras. Prim Care Companion J Clin Psychiatry 2002, 4(5):191.
• [39]Diez-Quevedo C, Rangil T, Sanchez-Planell L, Kroenke K, Spitzer RL: Validation and utility of the patient health questionnaire in diagnosing mental disorders in 1003 general hospital Spanish inpatients. Psychosom Med 2001, 63(4):679-86.
• [40]Zhong Q, Gelaye B, Fann JR, Sanchez SE, Williams MA: Cross-cultural validity of the Spanish version of PHQ-9 among pregnant Peruvian women: A Rasch item response theory analysis. J Affect Disord 2014, 158:148-53.
• [41]Altman DG, Bland JM: Statistics notes: the normal distribution. BMJ 1995, 310(6975):298.
• [42]Ghasemi A, Zahediasl S: Normality tests for statistical analysis: a guide for non-statisticians. Int J Endocrinol Metab 2012, 10(2):486-9.
• [43]Hsieh CC, Maisonneuve P, Boyle P, Macfarlane GJ, Roberston C: Analysis of quantitative data by quantiles in epidemiologic studies: classification according to cases, noncases, or all subjects? Epidemiology 1991, 2(2):137-40.
• [44]Rothman KJ, Greenland S, Lash LT, Philadelphia PA: Modern Epidemiology. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia; 2008.
• [45]Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry J-M: Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002, 109(2):143-8.
• [46]Pallavi P, Sagar R, Mehta M, Sharma S, Subramanium A, Shamshi F, et al.: Serum neurotrophic factors in adolescent depression: gender difference and correlation with clinical severity. J Affect Disord 2013, 150(2):415-23.
• [47]Satomura E, Baba H, Nakano Y, Maeshima H, Suzuki T, Arai H: Correlations between brain-derived neurotrophic factor and clinical symptoms in medicated patients with major depression. J Affect Disord 2011, 135(1):332-5.
• [48]Varambally S, Naveen GH, Rao MG, Thirthalli J, Sharma R, Christopher R, et al.: Low serum brain derived neurotrophic factor in non-suicidal out-patients with depression: Relation to depression scores. Indian J Psychiatry 2013, 55(Suppl 3):S397-9.
• [49]Jevtović S, Karlović D, Mihaljević-Peleš A, Serić V, Vrkić N, Jakšić N: Serum Brain-derived neurotrophic factor (BDNF): the severity and symptomatic dimensions of depression. Psychiatr Danub 2011, 23(4):363-9.
• [50]Birkenhäger TK, Geldermans S, Van den Broek WW, van Beveren N, Fekkes D: Serum brain-derived neurotrophic factor level in relation to illness severity and episode duration in patients with major depression. J Psychiatr Res 2012, 46(3):285-9.
• [51]de Azevedo Cardoso T, Mondin TC, Wiener CD, Marques MB, de Ávila Fucolo B, Pinheiro RT, de Souza LDM, da Silva RA, Jansen K, Oses JP: Neurotrophic factors, clinical features and gender differences in depression. Neurochem Res 2014, 39(8):1571-8.
• [52]Elfving B, Plougmann PH, Wegener G: Detection of brain-derived neurotrophic factor (BDNF) in rat blood and brain preparations using ELISA: pitfalls and solutions. J Neurosci Methods 2010, 187(1):73-7.
• [53]Wu A, Ying Z, Gomez-Pinilla F: Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J Neurotrauma 2004, 21(10):1457-67.
• [54]Bhatia HS, Agrawal R, Sharma S, Huo YX, Ying Z, Gomez-Pinilla F: Omega-3 fatty acid deficiency during brain maturation reduces neuronal and behavioral plasticity in adulthood. PLoS One 2011, 6(12):e28451.
• [55]Warner-Schmidt JL, Duman RS: Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 2006, 16(3):239-49.
• [56]Taliaz D, Stall N, Dar D, Zangen A: Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis. Mol Psychiatry 2009, 15(1):80-92.
• [57]Franklin TB, Perrot-Sinal TS: Sex and ovarian steroids modulate brain-derived neurotrophic factor (BDNF) protein levels in rat hippocampus under stressful and non-stressful conditions. Psychoneuroendocrinology 2006, 31(1):38-48.
• [58]Vellucci S, Parrott R, Mimmack M: Down-regulation of BDNF m RNA, with no effect on trkB or glucocorticoid receptor m RNA s, in the porcine hippocampus after acute dexamethasone treatment. Res Vet Sci 2001, 70(2):157-63.
• [59]Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, et al.: Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003, 54(1):70-5.
• [60]Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT: Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001, 50(4):260-5.
• [61]Castren E, Voikar V, Rantamaki T: Role of neurotrophic factors in depression. Curr Opin Pharmacol 2007, 7(1):18-21.
• [62]Lee HY, Kim YK: Plasma brain-derived neurotrophic factor as a peripheral marker for the action mechanism of antidepressants. Neuropsychobiology 2008, 57(4):194-9.
• [63]Tadic A, Wagner S, Schlicht KF, Peetz D, Borysenko L, Dreimuller N, et al.: The early non-increase of serum BDNF predicts failure of antidepressant treatment in patients with major depression: a pilot study. Prog Neuropsychopharmacol Bol Psychiatry 2011, 35(2):415-20.
• [64]Yoshimura R, Mitoma M, Sugita A, Hori H, Okamoto T, Umene W, et al.: Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Bol Psychiatry 2007, 31(5):1034-7.
• [65]Yang L, Zhang Z, Sun D, Xu Z, Yuan Y, Zhang X, et al.: Low serum BDNF may indicate the development of PSD in patients with acute ischemic stroke. Int J Geriatr Psychiatry 2011, 26(5):495-502.
• [66]Gilbody S, Richards D, Brealey S, Hewitt C: Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. J Gen Intern Med 2007, 22(11):1596-602.
• [67]Patel V, Araya R, Chowdhary N, King M, Kirkwood B, Nayak S, et al.: Detecting common mental disorders in primary care in India: a comparison of five screening questionnaires. Psychol Med 2008, 38(2):221-8.
• [68]Martinowich K, Manji H, Lu B: New insights into BDNF function in depression and anxiety. Nat Neurosci 2007, 10(9):1089-93.
• [69]Pang PT, Teng HK, Zaitsev E, Woo NT, Sakata K, Zhen S, et al.: Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 2004, 306(5695):487-91.
• [70]Woo NH, Teng HK, Siao CJ, Chiaruttini C, Pang PT, Milner TA, et al.: Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat Neurosci 2005, 8(8):1069-77.
• [71]Adewuya AO, Ola BA, Dada AO, Fasoto OO: Validation of the Edinburgh postnatal depression scale as a screening tool for depression in late pregnancy among Nigerian women. J Psychosom Obstet Gynaecol 2006, 27(4):267-72.
• [72]Sidebottom AC, Harrison PA, Godecker A, Kim H: Validation of the Patient Health Questionnaire (PHQ)-9 for prenatal depression screening. Arch Womens Ment Health 2012, 15(5):367-74.
• [73]Oates M: Perinatal psychiatric disorders: a leading cause of maternal morbidity and mortality. British Medical Bulletin 2003, 67:219-29.